Related Experiment Video
Updated: Jul 15, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Adjuvant chemotherapy for non-small cell lung cancer
Emilio Bria1, Federica Cuppone, Fabiana Letizia Cecere
1Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy. emiliobria@yahoo.it
Summary
Cisplatin-based chemotherapy improves survival for early-stage non-small cell lung cancer patients. This adjuvant treatment shows significant benefits for Stage II and IIIA, but not Stage IB lung cancer.
Area of Science:
- Oncology
- Thoracic Surgery
- Clinical Trials
Background:
- Cisplatin-based chemotherapy is a standard treatment for lung cancer.
- Previous meta-analyses and randomized clinical trials (RCTs) have evaluated adjuvant cisplatin chemotherapy.
- Evidence suggests benefits for Stage II and IIIA non-small cell lung cancer (NSCLC), but not Stage IB.
Purpose of the Study:
- To present an updated individual patient data-pooled analysis of recent RCTs.
- To evaluate the benefits of adjuvant cisplatin-based chemotherapy after surgery for early-stage NSCLC.
- To confirm findings from previous literature-based meta-analyses.
Main Methods:
- Individual patient data-pooled analysis of recent randomized clinical trials.
- Focus on adjuvant cisplatin-based chemotherapy following surgery for early-stage NSCLC.
- Analysis of overall survival and relative risk reduction.
Main Results:
- A 5-year overall survival benefit of 5.3% favoring cisplatin-based chemotherapy (48.8% vs 43.3%, p=0.004).
- A relative risk reduction of 11% in favor of cisplatin-based chemotherapy.
- Confirms previous meta-analysis findings regarding the efficacy of adjuvant cisplatin chemotherapy.
Conclusions:
- Adjuvant cisplatin-based chemotherapy offers a significant survival benefit for early-stage NSCLC patients.
- Personalized therapy based on molecular/genetic features is a promising future direction for optimizing treatment selection.
- Cisplatin remains a crucial component in lung cancer chemotherapy regimens.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...